Bethesda, Md. – The Parenteral Drug Association (PDA) today announced the appointment of former Eli Lilly and Co. - Executive Glenn E. Wright as Vice President of Scientific and Regulatory Affairs, effective March 23. Mr. Wright most recently worked as Senior Director of Quality Operations at Exelead, a contract manufacturer. Mr. Wright also has worked for Amgen and Pfizer.
Mr. Wright’s career at Eli Lilly spanned more than 20 years, during which he served in a variety of functions that give him unique experience in both pharmaceutical science and regulatory affairs. These roles included auditor, QC manager, global regulatory affairs director, and senior director of manufacturing science and technology. Mr. Wright also spent nearly four years working at Eli Lilly Italia as the company’s quality head for Italy, where he set quality policy for device and sterile products manufacturing and distribution operations including the plant’s modernization and repurposing from dry products to sterile insulin filling.
“Mr. Wright’s long experience in sterile pharmaceutical manufacturing, control, and regulatory affairs will prove invaluable to PDA’s members,” said Richard Johnson, President and CEO, PDA. “I have known Glenn a long time both during my time as PDA President and as a volunteer before that, and I am confident Mr. Wright will be an excellent leader of PDA’s various regulatory and manufacturing science activities.”
Mr. Wright has been active with PDA since 1990. He served over 12 years on the PDA Board of Directors, over 10 years on the PDA Science Advisory Board, and most recently as co-chair of the PDA’s Aging Facilities Task Force and as co-chair of PDA’s Manufacturing Science and Operations Program. Mr. Wright also served as the chairman of the Product Quality Research Institute’s working groups on aseptic processing and working group on post approval changes for sterile products. Mr. Wright has received numerous industry awards and citations including the prestigious Frederick J. Carleton Award for his outstanding contributions to the PDA Board and the wider organization.
As PDA’s VP of Scientific and Regulatory Affairs, Mr. Wright will oversee PDA’s scientific and regulatory affairs activities, which include developing industry-leading technical reports, the standards program through the American National Standards Institute (ANSI), regulatory commenting, and collaborating with PDA’s technical/regulatory advisory boards.
Dr. Tina Morris joined PDA in 2018 and oversaw the development of PDA’s first six standards. She leaves PDA to become the American Association of Pharmaceutical Science’s executive director.
“PDA appreciates Dr. Morris’s leadership during a time when PDA was drafting its first standards,” said Johnson. “We know AAPS will be in capable hands, and we wish her good fortune in her new role.”